 Intra-Cellular Therapies Inc NASDAQ: ITCI submits CAPLYTA lumateperone supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults. The application seeks approval for two indications of CAPLYTA; as monotherapy and as adjunctive therapy with lithium or valproate. 